InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,913.20
(
-0.86%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.25
(
0.03%
)
Bitcoin
63,954.84
(
-0.51%
)
Post# of 1189
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

MikeCr

Send PM Follow Ignore
Followers 42
Posts 5506
Boards Moderated 0
Alias Born 01/28/2010

MikeCr

Re: None

Wednesday, 12/12/2018 7:42:58 PM

Wednesday, December 12, 2018 7:42:58 PM

Post# of 1189

InterVenn BioSciences Raises $9.4M in Funding
Dec 12, 2018 | staff reporter
NEW YORK (GenomeWeb) – Diagnostics company InterVenn BioSciences said today it has raised $9.4 million in a funding round led by Genoa Ventures.

The Redwood City, California-based firm will use the funds to develop its lead product, a mass spectrometry-based blood test for ovarian cancer. The company said it is currently doing analytical and clinical validation for the test, which it ultimately plans to offer as a laboratory-developed test.


https://www.genomeweb.com/business-news/intervenn-biosciences-raises-94m-funding#.XBGp8mhKjIU

And yet over 10 years Avant was not able to raise any money to fund the OvaDx ovarian cancer test that they say is supposed to be so accurate.
Hmmm I wonder why?
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up